You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)投資於研發生產新冠疫苗企業 涉資5.15億美元
阿思達克 12-07 09:39
中生製藥(01177.HK)公布,集團全資附屬公司香港俊領有限公司就以5.15億美元向北京科興中維生物技術有限公司出資立協議。於出資完成後,中生製藥將於科興中維的註冊資本中擁有15.03%權益。科興中維將於中生製藥的財務報表中入賬列為聯營公司。

科興中維主要從事人用疫苗的研發業務,在新型冠狀病毒肺炎疫苗CoronaVac的開發取得了重大進展,是目前中國為數不多自行研發生產新冠疫苗的企業之一。於2020年4月13日,CoronaVac正式獲得中國國家藥品監督管理局批准進行臨床研究,隨後又獲得了巴西、印尼、土耳其及智利等國家的三期臨床試驗許可。目前,科興中維已獲得多國的疫苗訂單。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account